Health Economics›Primary mediastinal B-cell lymphoma›Relapsed or refractory salvage therapy

Relapsed or refractory salvage therapy

Primary mediastinal B-cell lymphoma · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
R-GDP Variant #01	—	R 30 037	21d	—	~31.1 mo	~6	~R 180 224 PFS proxy · indirect	1
R-DHAP Variant #01	—	R 29 945	21d	—	~31.1 mo	~3	~R 89 835 PFS proxy · indirect	2

2 of 2 regimens shown